Pramipexole dihydrochloride hydrate

Name: Pramipexole dihydrochloride hydrate
Brand: MedChemExpress
SKU: HY-B0410A
Rating: 5.0 (5 reviews)

Cat. No.: HY-B0410A Purity: ≥98.0%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Pramipexole dihydrochloride hydrate is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with K_is of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D₂, D₃ and D₄ receptors, respectively. Pramipexole dihydrochloride hydrate can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS).

For research use only. We do not sell to patients.

Pramipexole dihydrochloride hydrate Chemical Structure

CAS No. : 191217-81-9

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in Water ready for reconstitution	USD 55	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in Water	USD 55	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 32	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 50	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 150	In-stock	Estimated Time of Arrival: December 31
100 mg		Get quote
200 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 5 publication(s) in Google Scholar

Other Forms of Pramipexole dihydrochloride hydrate:

Dexpramipexole dihydrochloride In-stock
Pramipexole dihydrochloride In-stock
Dexpramipexole Get quote
Pramipexole Get quote
Pramipexole dihydrochloride hydrate (Standard) Get quote

5 Publications Citing Use of MCE Pramipexole dihydrochloride hydrate

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Dopamine Receptor Isoform Specific Products:

View All Isoforms

Dopamine Receptor D₁ Receptor D₂ Receptor D₃ Receptor D₄ Receptor D₅ Receptor

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

D₂ Receptor

3.9 nM (Ki)

D₃ Receptor

0.5 nM (Ki)

D₄ Receptor

1.3 nM (Ki)

In Vitro

Pramipexole dihydrochloride hydrate shows a low binding affinity for D1-type receptor, with an IC₅₀ of >50,000 nM^[1].
Pramipexole dihydrochloride hydrate (0.01-10 μM; 72 hours) produces dose-dependent increases of dendritic arborization and soma size^[3].
Pramipexole dihydrochloride hydrate attenuates levodopa-induced toxicity in mesencephalic cultures^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Pramipexole dihydrochloride hydrate (0.25-1 mg/kg; i.p.) significantly reduces the infarction volume in animals^[5].
Pramipexole dihydrochloride hydrate improves neurological recovery^[5].
Pramipexole dihydrochloride hydrate prevents ischemic cell death via mitochondrial pathways in ischemic stroke^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar rats weighing 250-300 g (16-18 weeks old)^[5]
Dosage:	0.25 mg/kg, 1 mg/kg
Administration:	Intraperitoneal injection
Result:	Decreased infarction volume as compared to tMCAO (transient middle cerebral artery occlusion)-only animals.

Clinical Trial

Molecular Weight

302.26

Formula

C₁₀H₂₁Cl₂N₃OS

CAS No.

191217-81-9

Appearance

Solid

Color

White to off-white

SMILES

[H]Cl.NC1=NC(CC[C@H](NCCC)C2)=C2S1.[H]Cl.O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Store at room temperature, keep dry and cool

Solvent & Solubility

In Vitro:

H₂O : 100 mg/mL (330.84 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.3084 mL	16.5420 mL	33.0841 mL
5 mM	0.6617 mL	3.3084 mL	6.6168 mL
10 mM	0.3308 mL	1.6542 mL	3.3084 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2 mg/mL (6.62 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2 mg/mL (6.62 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2 mg/mL (6.62 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 100 mg/mL (330.84 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: ≥98.0%

Select Batch:

Data Sheet (274 KB) SDS (393 KB)

COA (246 KB) HNMR (141 KB)

Handling Instructions (2659 KB)

References

[1]. Kvernmo, T., et al. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther, 2006. 28(8): p. 1065-78. [Content Brief]

[2]. Takashi Okura, et al. Blood-brain barrier transport of pramipexole, a dopamine D2 agonist. Life Sci. 2007 Apr 3;80(17):1564-71. [Content Brief]

[3]. Ginetta Collo, et al. Ropinirole and Pramipexole Promote Structural Plasticity in Human iPSC-Derived Dopaminergic Neurons via BDNF and mTOR Signaling. Neural Plast. 2018; 2018: 4196961. [Content Brief]

[4]. P M Carvey, et al. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm (Vienna). 1997;104(2-3):209-28. [Content Brief]

[5]. Syed Suhail Andrabi, et al. Pramipexole prevents ischemic cell death via mitochondrial pathways in ischemic stroke. Dis Model Mech. 2019 Aug 1; 12(8): dmm033860. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O	1 mM	3.3084 mL	16.5420 mL	33.0841 mL	82.7102 mL
	5 mM	0.6617 mL	3.3084 mL	6.6168 mL	16.5420 mL
	10 mM	0.3308 mL	1.6542 mL	3.3084 mL	8.2710 mL
	15 mM	0.2206 mL	1.1028 mL	2.2056 mL	5.5140 mL
	20 mM	0.1654 mL	0.8271 mL	1.6542 mL	4.1355 mL
	25 mM	0.1323 mL	0.6617 mL	1.3234 mL	3.3084 mL
	30 mM	0.1103 mL	0.5514 mL	1.1028 mL	2.7570 mL
	40 mM	0.0827 mL	0.4136 mL	0.8271 mL	2.0678 mL
	50 mM	0.0662 mL	0.3308 mL	0.6617 mL	1.6542 mL
	60 mM	0.0551 mL	0.2757 mL	0.5514 mL	1.3785 mL
	80 mM	0.0414 mL	0.2068 mL	0.4136 mL	1.0339 mL
	100 mM	0.0331 mL	0.1654 mL	0.3308 mL	0.8271 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.